Compare Stocks: XBIT, UPB, ANIK, and IMRX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANIK Anika Therapeutics	$19.58 +1.8%	$20.69	$8.67 ▼ $22.88	$262.04M	0.21	92,120 shs	88,586 shs
IMRX Immuneering	$3.94 +5.3%	$4.61	$3.60 ▼ $8.48	$254.91M	0.46	717,829 shs	709,560 shs
UPB Upstream Bio	$4.70 +3.3%	$6.07	$4.36 ▼ $33.68	$257.42M	1.38	814,189 shs	1.19 million shs
XBIT XBiotech	$2.29 +4.1%	$2.23	$2.09 ▼ $3.44	$69.82M	0.79	35,098 shs	88,032 shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANIK Anika Therapeutics	0.00%	+2.51%	-6.72%	+25.51%	+111.90%
IMRX Immuneering	0.00%	-3.19%	-13.79%	-22.90%	-39.38%
UPB Upstream Bio	0.00%	-6.75%	-18.26%	-37.58%	-75.16%
XBIT XBiotech	0.00%	+4.57%	+5.53%	0.00%	-14.87%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANIK Anika Therapeutics	$19.58 +1.8%	$20.69	$8.67 ▼ $22.88	$262.04M	0.21	92,120 shs	88,586 shs
IMRX Immuneering	$3.94 +5.3%	$4.61	$3.60 ▼ $8.48	$254.91M	0.46	717,829 shs	709,560 shs
UPB Upstream Bio	$4.70 +3.3%	$6.07	$4.36 ▼ $33.68	$257.42M	1.38	814,189 shs	1.19 million shs
XBIT XBiotech	$2.29 +4.1%	$2.23	$2.09 ▼ $3.44	$69.82M	0.79	35,098 shs	88,032 shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANIK Anika Therapeutics	0.00%	+2.51%	-6.72%	+25.51%	+111.90%
IMRX Immuneering	0.00%	-3.19%	-13.79%	-22.90%	-39.38%
UPB Upstream Bio	0.00%	-6.75%	-18.26%	-37.58%	-75.16%
XBIT XBiotech	0.00%	+4.57%	+5.53%	0.00%	-14.87%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ANIK Anika Therapeutics	2.25	Hold	$22.00	12.36% Upside
IMRX Immuneering	3.00	Buy	$15.71	298.84% Upside
UPB Upstream Bio	2.43	Hold	$29.67	531.21% Upside
XBIT XBiotech	1.00	Sell	N/A	N/A

Current Analyst Ratings Breakdown

Latest XBIT, UPB, ANIK, and IMRX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/28/2026	XBIT XBiotech	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
9/28/2026	ANIK Anika Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
9/21/2026	ANIK Anika Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
9/21/2026	IMRX Immuneering	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
9/18/2026	ANIK Anika Therapeutics	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$21.00 ➝ $23.00
9/14/2026	XBIT XBiotech	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
9/2/2026	UPB Upstream Bio	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$36.00
9/1/2026	XBIT XBiotech	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/27/2026	IMRX Immuneering	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/18/2026	XBIT XBiotech	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/17/2026	UPB Upstream Bio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)

(Data available from 10/11/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ANIK Anika Therapeutics	$112.82M	2.32	N/A	N/A	$9.95 per share	1.97
IMRX Immuneering	N/A	N/A	N/A	N/A	$3.38 per share	N/A
UPB Upstream Bio	$2.85M	90.32	N/A	N/A	$6.29 per share	0.75
XBIT XBiotech	N/A	N/A	N/A	N/A	$4.60 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ANIK Anika Therapeutics	-$10.88M	-$0.27	N/A	67.52	13.99	-3.14%	0.20%	0.15%	11/4/2026 (Estimated)
IMRX Immuneering	-$56.03M	-$1.04	N/A	N/A	N/A	N/A	-27.15%	-25.75%	11/11/2026 (Estimated)
UPB Upstream Bio	-$143.44M	-$2.90	N/A	N/A	N/A	-4,955.67%	-48.40%	-46.57%	11/4/2026 (Estimated)
XBIT XBiotech	-$45.54M	-$1.48	N/A	N/A	N/A	N/A	-31.62%	-30.29%	N/A

Latest XBIT, UPB, ANIK, and IMRX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/4/2026	Q3 2026	ANIK Anika Therapeutics	$0.42	N/A	N/A	N/A	$29.44 million	N/A
11/4/2026	Q3 2026	UPB Upstream Bio	-$0.7286	N/A	N/A	N/A	$0.52 million	N/A
8/13/2026	Q2 2026	XBIT XBiotech	$0.03	-$0.22	-$0.25	-$0.22	$7.00 million	N/A
8/11/2026	Q2 2026	UPB Upstream Bio	-$0.7444	-$0.73	+$0.0144	-$0.73	$0.56 million	$0.77 million
8/5/2026	Q2 2026	IMRX Immuneering	-$0.2643	-$0.27	-$0.0057	-$0.27	N/A	N/A
7/29/2026	Q2 2026	ANIK Anika Therapeutics	$0.03	$0.42	+$0.39	$0.24	$29.21 million	$32.61 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ANIK Anika Therapeutics	N/A	N/A	N/A	N/A	N/A
IMRX Immuneering	N/A	N/A	N/A	N/A	N/A
UPB Upstream Bio	N/A	N/A	N/A	N/A	N/A
XBIT XBiotech	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ANIK Anika Therapeutics	N/A	4.48	3.19
IMRX Immuneering	N/A	19.47	19.47
UPB Upstream Bio	N/A	27.99	27.99
XBIT XBiotech	N/A	33.15	33.15

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ANIK Anika Therapeutics	91.53%
IMRX Immuneering	67.65%
UPB Upstream Bio	N/A
XBIT XBiotech	55.70%

Insider Ownership

Company	Insider Ownership
ANIK Anika Therapeutics	12.08%
IMRX Immuneering	14.90%
UPB Upstream Bio	16.46%
XBIT XBiotech	30.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ANIK Anika Therapeutics	235	13.38 million	11.77 million	Optionable
IMRX Immuneering	57	64.70 million	55.06 million	Not Optionable
UPB Upstream Bio	75	54.77 million	45.76 million	N/A
XBIT XBiotech	87	30.49 million	24.06 million	Optionable

XBIT, UPB, ANIK, and IMRX Headlines

Recent News About These Companies

XBiotech (NASDAQ:XBIT) Share Price Breaks Below 50-Day Moving Average - Time to Sell?

October 3, 2026 | americanbankingnews.com

XBiotech Launches Phase II Clinical Trial Evaluating Vilamakitug for the Treatment of Active Axial Spondyloarthritis

June 15, 2026 | globenewswire.com

XBiotech’s New Axial Spondyloarthritis Trial Puts Vilamakitug on Investors’ Radar

May 14, 2026 | tipranks.com

XBiotech: Q4 Earnings Snapshot

March 13, 2026 | chron.com

XBiotech’s New Trial: A Potential Game-Changer for Rheumatoid Arthritis Treatment?

October 28, 2025 | msn.com

XBiotech Inc.'s (NASDAQ:XBIT) top owners are retail investors with 52% stake, while 36% is held by insiders

August 28, 2025 | finance.yahoo.com

The Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud Investigation

March 2, 2025 | accessnewswire.comA

An Investigation Has Been Launched Into XBiotech Inc. For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm

March 1, 2025 | accessnewswire.comA

The Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud Investigation

February 28, 2025 | accessnewswire.comA

An Investigation Has Been Launched Into XBiotech Inc. For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm

February 27, 2025 | accessnewswire.comA

The Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud Investigation

February 26, 2025 | accessnewswire.comA

An Investigation Has Been Launched Into XBiotech Inc. For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm

February 25, 2025 | accessnewswire.comA

The Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud Investigation

February 24, 2025 | accessnewswire.comA

An Investigation Has Been Launched Into XBiotech Inc. For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm

February 23, 2025 | accessnewswire.comA

The Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud Investigation

February 22, 2025 | accessnewswire.comA

An Investigation Has Been Launched Into XBiotech Inc. For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm

February 21, 2025 | accessnewswire.comA

The Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud Investigation

February 20, 2025 | accessnewswire.comA

The Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud Investigation

February 18, 2025 | accessnewswire.comA

XBiotech Inc. Is Being Investigated For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm

February 17, 2025 | accessnewswire.comA

The Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud Investigation

February 16, 2025 | accessnewswire.comA

New MarketBeat Followers Over Time

Media Sentiment Over Time

XBIT, UPB, ANIK, and IMRX Company Descriptions

Anika Therapeutics NASDAQ:ANIK

$19.58 +0.35 (+1.82%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$19.57 -0.01 (-0.08%)

As of 10/9/2026 07:30 PM Eastern

Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management products includes Monovisc and Orthovisc, an injectable HA-based viscosupplement for the pain relief from osteoarthritis conditions; and Cingal, a single-injection OA pain management product to provide both short- and long-term pain relief. The company's joint preservation and restoration product family comprises and orthopedic regenerative solutions, including Hyalofast and Tactoset; sports medicine solutions used to repair and reconstruct damaged ligaments and tendons; and preserving joint solutions, including partial joint replacement, joint resurfacing, and invasive and bone sparing implants, which are designed to treat upper and lower extremity orthopedic conditions. In addition, it offers non-orthopedic products comprising HA-based products for non-orthopedic applications including Hyvisc, a molecular weight injectable HA veterinary product; Hyalobarrier, an anti-adhesion barrier indicated for use after abdominal-pelvic surgeries; and Hyalomatrix used for the treatment of burns and ulcers, as well as products used for the treatment of ears, nose and throat disorders, and ophthalmic products. The company was founded in 1983 and is headquartered in Bedford, Massachusetts.

Immuneering NASDAQ:IMRX

$3.94 +0.20 (+5.35%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$3.94 0.00 (0.00%)

As of 10/9/2026 07:30 PM Eastern

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.

Upstream Bio NASDAQ:UPB

$4.70 +0.15 (+3.30%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$4.71 +0.01 (+0.21%)

As of 10/9/2026 07:30 PM Eastern

Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Upstream Bio, Inc. was incorporated in 2021 and is based in Waltham, Massachusetts.

XBiotech NASDAQ:XBIT

$2.29 +0.09 (+4.09%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$2.28 0.00 (-0.22%)

As of 10/9/2026 07:30 PM Eastern

XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation. The company was incorporated in 2005 and is headquartered in Austin, Texas.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest XBIT, UPB, ANIK, and IMRX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest XBIT, UPB, ANIK, and IMRX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

XBIT, UPB, ANIK, and IMRX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

XBIT, UPB, ANIK, and IMRX Company Descriptions

Anika Therapeutics NASDAQ:ANIK

Immuneering NASDAQ:IMRX

Upstream Bio NASDAQ:UPB

XBiotech NASDAQ:XBIT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest XBIT, UPB, ANIK, and IMRX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest XBIT, UPB, ANIK, and IMRX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

XBIT, UPB, ANIK, and IMRX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

XBIT, UPB, ANIK, and IMRX Company Descriptions

Anika Therapeutics NASDAQ:ANIK

Immuneering NASDAQ:IMRX

Upstream Bio NASDAQ:UPB

XBiotech NASDAQ:XBIT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools